INMB
Price
$7.09
Change
-$0.05 (-0.70%)
Updated
May 8, 04:59 PM (EDT)
Capitalization
164.11M
Earnings call today
ORMP
Price
$2.29
Change
+$0.08 (+3.60%)
Updated
May 8, 04:59 PM (EDT)
Capitalization
93.55M
20 days until earnings call
Ad is loading...

INMB vs ORMP

Header iconINMB vs ORMP Comparison
Open Charts INMB vs ORMPBanner chart's image
INmune Bio
Price$7.09
Change-$0.05 (-0.70%)
Volume$5.62K
Capitalization164.11M
Oramed Pharmaceuticals
Price$2.29
Change+$0.08 (+3.60%)
Volume$200
Capitalization93.55M
INMB vs ORMP Comparison Chart
Loading...
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INMB vs. ORMP commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INMB is a Hold and ORMP is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (INMB: $7.14 vs. ORMP: $2.22)
Brand notoriety: INMB and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INMB: 77% vs. ORMP: 30%
Market capitalization -- INMB: $164.11M vs. ORMP: $93.55M
INMB [@Biotechnology] is valued at $164.11M. ORMP’s [@Biotechnology] market capitalization is $93.55M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INMB’s FA Score shows that 0 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • INMB’s FA Score: 0 green, 5 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, ORMP is a better buy in the long-term than INMB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INMB’s TA Score shows that 2 TA indicator(s) are bullish while ORMP’s TA Score has 4 bullish TA indicator(s).

  • INMB’s TA Score: 2 bullish, 6 bearish.
  • ORMP’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ORMP is a better buy in the short-term than INMB.

Price Growth

INMB (@Biotechnology) experienced а -9.16% price change this week, while ORMP (@Biotechnology) price change was -4.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.88%. For the same industry, the average monthly price growth was +15.29%, and the average quarterly price growth was -13.75%.

Reported Earning Dates

INMB is expected to report earnings on Jul 30, 2025.

ORMP is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (-3.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INMB($164M) has a higher market cap than ORMP($93.5M). INMB YTD gains are higher at: 52.891 vs. ORMP (-8.264). ORMP has higher annual earnings (EBITDA): 9.44M vs. INMB (-41.55M). ORMP has more cash in the bank: 142M vs. INMB (33.6M). ORMP has less debt than INMB: ORMP (429K) vs INMB (2.91M). INMB has higher revenues than ORMP: INMB (42K) vs ORMP (0).
INMBORMPINMB / ORMP
Capitalization164M93.5M175%
EBITDA-41.55M9.44M-440%
Gain YTD52.891-8.264-640%
P/E RatioN/A20.91-
Revenue42K0-
Total Cash33.6M142M24%
Total Debt2.91M429K679%
FUNDAMENTALS RATINGS
INMB vs ORMP: Fundamental Ratings
INMB
ORMP
OUTLOOK RATING
1..100
6465
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
82100
SMR RATING
1..100
9579
PRICE GROWTH RATING
1..100
6253
P/E GROWTH RATING
1..100
10044
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (68) in the Pharmaceuticals Other industry is in the same range as INMB (97) in the Biotechnology industry. This means that ORMP’s stock grew similarly to INMB’s over the last 12 months.

INMB's Profit vs Risk Rating (82) in the Biotechnology industry is in the same range as ORMP (100) in the Pharmaceuticals Other industry. This means that INMB’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's SMR Rating (79) in the Pharmaceuticals Other industry is in the same range as INMB (95) in the Biotechnology industry. This means that ORMP’s stock grew similarly to INMB’s over the last 12 months.

ORMP's Price Growth Rating (53) in the Pharmaceuticals Other industry is in the same range as INMB (62) in the Biotechnology industry. This means that ORMP’s stock grew similarly to INMB’s over the last 12 months.

ORMP's P/E Growth Rating (44) in the Pharmaceuticals Other industry is somewhat better than the same rating for INMB (100) in the Biotechnology industry. This means that ORMP’s stock grew somewhat faster than INMB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INMBORMP
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
69%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 16 days ago
84%
Bullish Trend 16 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 2 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SIEYX13.02N/A
N/A
Saratoga International Equity A
GSPIX37.98N/A
N/A
Goldman Sachs Large Cap Equity Instl
DNLDX56.87N/A
N/A
BNY Mellon Active MidCap A
GIRLX14.03N/A
N/A
Goldman Sachs Intl Sm Cp Insghts Inv
DHPIX16.24N/A
N/A
Diamond Hill Mid Cap I

INMB and

Correlation & Price change

A.I.dvisor indicates that over the last year, INMB has been loosely correlated with ABCL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if INMB jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INMB
1D Price
Change %
INMB100%
+0.14%
ABCL - INMB
46%
Loosely correlated
-0.99%
ATOS - INMB
43%
Loosely correlated
-2.30%
PRME - INMB
42%
Loosely correlated
+6.77%
RARE - INMB
41%
Loosely correlated
-4.68%
CRSP - INMB
41%
Loosely correlated
+3.29%
More

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with BTAI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then BTAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
-0.45%
BTAI - ORMP
44%
Loosely correlated
-3.16%
INO - ORMP
44%
Loosely correlated
+2.92%
MBIO - ORMP
44%
Loosely correlated
+0.44%
VERV - ORMP
44%
Loosely correlated
-3.21%
ZNTL - ORMP
43%
Loosely correlated
-1.60%
More